Bicycle Therapeutics plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin Lee
- Full Time Employees
- 305
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Babraham Research Campus Cambridge United Kingdom CB22 3AT
- IPO Date
- May 23, 2019
- CIK
- 0001761612
- Website
- bicycletherapeutics.com
- Similar Companies
- Business
- Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Cambridge, United Kingdom, develops a novel class of precision-guided therapeutics known as Bicycle molecules, fully synthetic short peptides constrained by small molecule scaffolds to form two loops that enable high-affinity target binding and selectivity; these include Bicycle Drug Conjugates (BDCs), Bicycle Tumor-Targeted Immune Cell Agonists (Bicycle TICAs), and Bicycle Radioconjugates (BRCs) primarily targeting solid tumors in oncology, with applications explored beyond cancer in areas such as anti-infective, cardiovascular, ophthalmology, dementia, central nervous system, neuromuscular, and respiratory diseases through partnerships. Core products in clinical development encompass zelenectide pevedotin (formerly BT8009), a Nectin-4-targeted BDC in Phase 2/3 pivotal Duravelo-2 trial for metastatic urothelial cancer (mUC) combined with pembrolizumab, Phase 1/2 Duravelo-3 for Nectin-4-amplified breast cancer, and Phase 1/2 Duravelo-4 for Nectin-4-amplified non-small cell lung cancer (NSCLC), both actively enrolling following FDA Fast Track designations; BT5528, an EphA2-targeted BDC in Phase 1 with upcoming combination data presentations in 1H 2026; BT7480, a Nectin-4/CD137 Bicycle TICA in Phase 1 with combination data expected in 1H 2026; and an emerging BRC pipeline targeting MT1-MMP with preclinical and first human imaging data presented at EANM 2025 Congress supporting radiotheranostic potential, alongside EphA2 imaging data anticipated in 1H 2026. The company maintains strategic collaborations with biopharmaceutical firms including Bayer, Novartis, and Genentech for therapeutic development across multiple indications. Recent developments include a strategic workforce reduction of approximately 30% announced in Q2 2025 to enhance operational flexibility and extend cash runway into 2028 with $648.3 million in cash equivalents as of September 30, 2025 plus $38.2 million U.K. R&D tax credit received in October 2025; strengthened leadership through Board additions of Charles Swanton M.D. Ph.D., Roger Dansey M.D., and Hervé Hoppenot, alongside expansion of the Research and Innovation Advisory Board with experts Steve Davidsen Ph.D., Gilles Gallant Ph.D., Ken Herrmann M.D. MBA, and John Lambert Ph.D.; advancement of zelenectide pevedotin with regulatory feedback sought for Duravelo-2 dose selection and approval pathway updates planned for Q1 2026; and presentations of Duravelo-3/4 trial progress and BRC data at ESMO Congress 2025.
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analysts
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerages
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky